Evidence map›Paper›PMID 23505481›Full record

ArticlePloS one2013

FMR1 transcript isoforms: association with polyribosomes; regional and developmental expression in mouse brain.

David M Brackett, Feng Qing, Paul S Amieux, Drew L Sellers, Philip J Horner, David R Morris

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Review
  3. Anterior piriform cortex dysfunction underlies autism spectrum disorders-related olfactory deficits in Fmr1 conditional deletion mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  4. Cells · 2024
    Review
  5. Size matters: Fighting repeat expansion size in fragile X syndrome using antisense oligonucleotides.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Gene therapy using human FMRP isoforms driven by the humanMolecular therapy. Methods & clinical development · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Genes · 2021
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

David M BrackettDepartment of Biochemistry, University of Washington, Seattle, Washington, United States of America.
Feng Qing
Paul S Amieux
Drew L Sellers
Philip J Horner
David R Morris
University of Washington · USNeurological Surgery · US

Funding

Restoring FMRP Phenotypes Frpm Temporal Regional and Splice- Isoforms VarationsP30HD002274 · NICHD · UNIVERSITY OF WASHINGTON · PI GURALNICK, MICHAEL J · 1985 to 2013
$33.6M
Cell-specific Transcript Profiling in Complex TissuesR21RR021704 · NCRR · UNIVERSITY OF WASHINGTON · PI MORRIS, DAVID R · 2006 to 2007
$422k
NCRR NIH HHS 1R21RR021704-02NCRR NIH HHS R21 RR021704NICHD NIH HHS P30 HD002274NICHD NIH HHS P30 HD02274-S
6 · The paper itself

Abstract

The primary transcript of the mammalian Fragile X Mental Retardation-1 gene (Fmr1), like many transcripts in the central nervous system, is alternatively spliced to yield mRNAs encoding multiple proteins, which can possess quite different biochemical properties. Despite the fact that the relative levels of the 12 Fmr1 transcript isoforms examined here vary by as much as two orders of magnitude amongst themselves in both adult and embryonic mouse brain, all are associated with polyribosomes, consistent with translation into the corresponding isoforms of the protein product, FMRP (Fragile X Mental Retardation Protein). Employing the RiboTag methodology developed in our laboratory, the relative proportions of the 7 most abundant transcript isoforms were measured specifically in neurons and found to be similar to those identified in whole brain. Measurements of isoform profiles across 11 regions of adult brain yielded similar distributions, with the exceptions of the hippocampus and the olfactory bulb. These two regions differ from most of the brain in relative amounts of transcripts encoding an alternate form of one of the KH RNA binding domains. A possible relationship between patterns of expression in the hippocampus and olfactory bulb and the presence of neuroblasts in these two regions is suggested by the isoform patterns in early embryonic brain and in cultured neural progenitor cells. These results demonstrate that the relative levels of the Fmr1 isoforms are modulated according to developmental stage, highlighting the complex ramifications of losing all the protein isoforms in individuals with Fragile X Syndrome. It should also be noted that, of the eight most prominent FMRP isoforms (1-3, 6-9 and 12) in mouse, only two have the major site of phosphorylation at Ser-499, which is thought to be involved in some of the regulatory interactions of this protein.

Indexed as

Gene Expression RegulationRNA IsoformsAlternative SplicingAnimalsBrainCells, CulturedFragile X Messenger Ribonucleoprotein 1Gene Expression Regulation, DevelopmentalGene OrderMaleMiceNeural Stem CellsPolyribosomesFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1RNA Isoforms

Identifiers

PMID23505481
PMCPMC3591412
OpenAlexW2028248368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.